EUVIMEDOpdag EUVIMED
Open access

Engineering IGF2 for Lysosome‐targeting chimeras development to target drug‐resistant membrane proteins in tumor therapy

Yanchao Pan iD, Qing Xiang, Kai Deng, Muhammad I Anwar, Leiming Wang, Yuan Wang, Qiulian Liang, Lirou Shen, Jing Yang, Zhongyu Hou, Weijun Shen

Protein Science · 2025-03 · 34 (3)

DOI: 10.1002/pro.70051 ↗

At a glance

Journal article in Protein Science, published online on 2025-02-19. Written by Yanchao Pan and 10 co-authors. Institution: Translational Research Center, Shenzhen Bay Laboratory, Shenzhen, China. Major MEDLINE topics: Lysosomes, Insulin-Like Growth Factor II, Drug Resistance, Neoplasm, Protein Engineering. Cited 18 times so far (Crossref); 32 references. The full text is freely available in PubMed Central. Funded by: Shenzhen Bay Laboratory.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Lysosome‐targeting chimeras (LYTACs) represent a promising approach for the targeted degradation of membrane proteins. Currently, two primary methods for LYTAC development involve chemically modified antibodies and wild‐type insulin‐like growth factor 2 (IGF2) fusion proteins (iLYTACs). However, LYTACs necessitate intricate chemical modification processes, while wild‐type IGF2 in iLYTAC technology binds to IGF1R, potentially triggering carcinogenesis. To tackle this challenge, we introduce specific IGF2R‐binding lysosomal targeting chimeras (sLYTACs), a novel technology utilizing engineered IGF2 mutant fusion antibodies for the degradation of endogenous membrane proteins. Diverging from iLYTACs, sLYTACs exhibit selective binding to IGF2R with increased affinity, significantly bolstering the anti‐proliferative impact on drug‐resistant tumor cells both in vitro and in vivo. By effectively degrading third‐generation tyrosine kinase inhibitor‐resistant EGFR mutants, masking binding epitope HER2, and concurrently targeting compensatory receptors interacting with these proteins, sLYTACs show great promise in drug development to overcome bypass signaling and combat drug resistance in tumors.

Subjects

MeSH terms (MEDLINE)

LysosomesInsulin-Like Growth Factor IIDrug Resistance, NeoplasmProtein EngineeringRecombinant Fusion ProteinsNeoplasmsMembrane ProteinsHumansAnimalsCell Line, TumorMiceReceptor, IGF Type 2ErbB ReceptorsAntineoplastic AgentsErb-b2 Receptor Tyrosine Kinases

Author keywords

IGF2 engineeringdrug resistanceprotein degradationspecific IGF2R‐binding lysosomal targeting chimeras

Substances

Insulin-Like Growth Factor IIRecombinant Fusion ProteinsReceptor, IGF Type 2Membrane ProteinsErbB ReceptorsAntineoplastic AgentsErb-b2 Receptor Tyrosine KinasesIGF2 protein, humanIGF2R protein, human

Authors and institutions

  • Translational Research Center, Shenzhen Bay Laboratory, Shenzhen, China.

ORCID profiles: Yanchao Pan

Funding

  • Shenzhen Bay Laboratory

Cite

APA

Pan, Y., Xiang, Q., Deng, K., Anwar, M. I., Wang, L., Wang, Y., Liang, Q., Shen, L., Yang, J., Hou, Z., & Shen, W. (2025). Engineering IGF2 for Lysosome‐targeting chimeras development to target drug‐resistant membrane proteins in tumor therapy. Protein Science, 34(3). https://doi.org/10.1002/pro.70051

Vancouver

Pan Y, Xiang Q, Deng K, Anwar MI, Wang L, Wang Y, et al. Engineering IGF2 for Lysosome‐targeting chimeras development to target drug‐resistant membrane proteins in tumor therapy. Protein Science. 2025;34(3). doi:10.1002/pro.70051

BibTeX
@article{Pan2025,
  author = {Pan, Yanchao and Xiang, Qing and Deng, Kai and Anwar, Muhammad I and Wang, Leiming and Wang, Yuan and Liang, Qiulian and Shen, Lirou and Yang, Jing and Hou, Zhongyu and Shen, Weijun},
  title = {Engineering IGF2 for Lysosome‐targeting chimeras development to target drug‐resistant membrane proteins in tumor therapy},
  journal = {Protein Science},
  year = {2025},
  volume = {34},
  number = {3},
  doi = {10.1002/pro.70051}
}
Start for free →